VRS.L

Versarien Plc
Versarien PLC - Medical Technology Collaboration
21st February 2018, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4572F
Versarien PLC
21 February 2018
 

Versarien plc

("Versarien" or the "Company")

Medical Technology Collaboration

 

Versarien plc (AIM: VRS), the advanced materials engineering group, is pleased to announce that it has signed an agreement to develop a range of graphene based sensor technologies to enable the creation of digital bandages and wound dressings capable of various forms of physiological movement and excretion detection.

This project will utilise strain sensors printed with graphene ink using methods which have been developed by the Company's subsidiary, Cambridge Graphene Limited.  Trials will take place at the internationally renowned Addenbrooke's Hospital in Cambridge with Orthopaedic surgeon Dr Arman Memanzedah leading the clinical trials.  He will be joined by Dr Simon Rudland from Stowhealth who will be working with the team to optimise the usability of the data from the graphene dressings to ensure the optimal recovery of the patients post discharge.  The agreement will also involve Dr Chris Crockford, Managing Director of Digital and Future Technologies Limited, who will act as liaison between the hospital, Versarien and wider global providers in this field.

Neill Ricketts, CEO of Versarien, commented: "We are very pleased to be working to bring our graphene ink technology to the medical arena.  This is our first collaboration in this area and we anticipate that the properties of the high quality graphene we produce can bring significant benefits.  In particular, the incorporation of graphene inks will enable the development of 'smart' wound dressings, facilitating better patient monitoring and enhanced recovery.

"We are very excited about the potential for graphene in a variety of medical uses and anticipate entering into further collaborations in this area in due course."

 

Enquiries:

Versarien                                                                                          01242 269 122

Neill Ricketts, CEO

Chris Leigh, CFO

WH Ireland (Nominated Advisor)                                                    0117 945 3470

Mike Coe

Ed Allsopp

IFC Advisory (Financial PR and IR)                                                0203 934 6630                

Tim Metcalfe

Graham Herring

Heather Armstrong

 

About Versarien

Versarien plc (AIM:VRS), is an advanced engineering materials group. Leveraging proprietary technology, the Group creates innovative engineering solutions for its clients in a diverse range of industries. Versarien has five subsidiaries operating under two divisions:

Graphene and Plastics

2-DTech Ltd, which specialises in the supply, characterisation and early stage development of graphene products. www.2-dtech.com  

ACC Cyroma Ltd, which specialises in the supply of vacuum-formed and injection-moulded products to the automotive, construction, utilities and retail industry sectors. Using Versarien's existing graphene manufacturing capabilities, AAC will have the ability to produce graphene-enhanced plastic products.  www.aaccyroma.co.uk  

Cambridge Graphene Ltd, which supplies novel inks based on graphene and related materials, using patented processes and develops graphene materials technology for licensing to manufacturers.  www.cambridgegraphene.com 

Thermal and Hard Wear Products

Versarien Technologies Ltd. which owns the exclusive rights to a patent-protected additive process for creating advanced micro-porous metals targeting the thermal management industry and manufactures extruded aluminium heat sinks for the electronics and computing industries. www.versarien-technologies.co.uk 

Total Carbide Ltd, a leading manufacturer in sintered tungsten carbide for applications in arduous environments such as the oil and gas industry. www.totalcarbide.com 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABBLLLVLFEBBQ ]]>
TwitterFacebookLinkedIn